Beam Therapeutics

#4809

Rank

$1.69B

Marketcap

United States

Country

Leadership team

Mr. John M. Evans M.B.A. (CEO & Director)

Dr. Giuseppe Ciaramella Ph.D. (Pres & Chief Scientific Officer)

Ms. Terry-Ann Burrell M.B.A. (CFO & Treasurer)

Products/ Services

Biotechnology, Genetics, Medical, Therapeutics

Number of Employees

100 - 500

Headquarters

Cambridge, Massachusetts, United States

Established

2017

Company Registration

SEC CIK number: 0001745999

Revenue

20M - 100M

Traded as

BEAM

Social Media

URL

https://www.beamtx.com

Overview

Location

Recognition and Award

References

Summary

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

History

Founded in 2017, the company traces its origins to the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Co-founders include David R. Liu and Feng Zhang. Prior to its IPO, the company raised nearly $1 billion in venture capital from investors. In a February 2020 IPO, the company raised $180 million.In January 2022, Pfizer and Beam Therapeutics announced a collaboration to develop therapies for rare diseases using CRISPR.

Mission

To revolutionize genetic medicine through precise and efficient gene editing to deliver meaningful therapies to patients in need.

Vision

To create and commercialize medicines that will fundamentally change the practice of genetic medicine.

Key Team

Dr. Feng Zhang Ph.D. (Co-Founder)

Dr. David R. Liu Ph.D. (Co-Founder)

Dr. J. Keith Joung M.D., Ph.D. (Co-Founder)

Dr. Alexis Komor Ph.D. (Co-Founder)

Ms. Suzanne Fleming (Chief Accounting Officer)

Dr. Nicole Gaudelli Ph.D. (Co-Founder)

Mr. Brian Riley (Sr. VP of Technical Operations)

Recognition and Awards

Beam has been recognized by many awards and accolades, including being named one of the “40 Hottest Companies in the Field of Gene-Editing & CRISPR-Based Therapeutics” in 2019 and one of “4 Cutting-Edge Companies for 2020” by the World Economic Forum. Additionally, Beam has received recognition from PWC, Deloitte, Frost & Sullivan, and the European Medicines Agency among many others.